Maybe in the future, siRNAs targeting IGF-IR will be modified in order to improve the effect of IGF-IR downregulation and consequently modulate antitumor immune responses with the aim to offer a new clinical approach for treatment of mammary tumors expressing IGF-IR. The gene discussed is IGF1R; the disease is breast cancer.